Animal health company Zoetis (NYSE: ZTS) will be announcing earnings results tomorrow before market hours. Here’s what investors should know.
Zoetis met analysts’ revenue expectations last quarter, reporting revenues of $2.32 billion, up 4.7% year on year. It was a softer quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.
Is Zoetis a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Zoetis’s revenue to be flat year on year at $2.19 billion, slowing from the 9.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.40 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zoetis has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Zoetis’s peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb’s revenues decreased 5.6% year on year, beating analysts’ expectations by 3.9%, and Organon reported a revenue decline of 6.7%, topping estimates by 0.6%. Bristol-Myers Squibb traded down 1.3% following the results while Organon was also down 25.8%.
Read our full analysis of Bristol-Myers Squibb’s results here and Organon’s results here.
There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 4.9% on average over the last month. Zoetis is up 6.2% during the same time and is heading into earnings with an average analyst price target of $195.49 (compared to the current share price of $158.30).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
